Dermatological adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex-Reference-Cited by-同舟云学术

Dermatological adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex

Published:2020-05-26 Issue:3 Volume:183 Page:588-589
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Pithadia D.J.¹²^ORCID,Treichel A.M.¹²^ORCID,Jones A.M.²,Julien‐Williams P.²,Machado T.²,Moss J.²,Darling T.N.¹^ORCID

Affiliation:

1. Department of Dermatology Uniformed Services University Bethesda MD USA

2. Pulmonary Branch National Heart, Lung, and Blood Institute National Institutes of Health Bethesda MD USA

Funder

Doris Duke Charitable Foundation Clinical Research Mentorship Grant

National Institutes of Health, Medical Research Scholars Program

Intramural Research Program, National Heart, Lung, and Blood Institute, National Institutes of Health

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19124

Reference8 articles.

1. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex

2. Mammalian target of rapamycin inhibitor-associated stomatitis

3. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

4. mTOR signaling promotes stem cell activation via counterbalancing BMP-mediated suppression during hair regeneration

5. Acne in recipients of renal transplantation treated with sirolimus: Clinical, microbiologic, histologic, therapeutic, and pathogenic aspects

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuberous Sclerosis Complex and Cancer;Turkish Journal of Oncology;2023

2. Sirolimus;Reactions Weekly;2020-10